Specific antibody in IV immunoglobulin for postsplenectomy sepsis

Critical Care Medicine

Volumn 41, Issue 8, 2013, Pages

  Nakamura, Kensuke ^a   Doi, Kent ^a   Okamoto, Koji ^a   Arai, Syunnya ^a   Ueha, Satoshi ^a   Matsushima, Kouji ^a   Nakajima, Susumu ^a   Yahagi, Naoki ^a   Noiri, Eisei ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Immunomodulation; IV immunoglobulin; Macrophage; Marginal zone B cell; Overwhelming postsplenectomy infection; Pneumococcus; Sepsis; Specific antibody; Splenectomy; Streptococcus pneumoniae

Indexed keywords

ANTIBODY; BACTERIUM ANTIBODY; IMMUNOGLOBULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE ACTIVATION; BACTERIAL COUNT; BACTERIAL STRAIN; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; FLUORESCENCE MICROSCOPY; IMMUNOMODULATION; IMMUNOPRECIPITATION; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; SEPSIS; SHAM PROCEDURE; SPLENECTOMY; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE; UNIVERSITY;

ANIMALS; ANTIBODIES, BACTERIAL; B-LYMPHOCYTES; BACTERIAL LOAD; BLOOD; CYTOKINES; FLOW CYTOMETRY; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOPRECIPITATION; LIVER; MALE; MICE; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; PHAGOCYTOSIS; PROSPECTIVE STUDIES; RANDOM ALLOCATION; SEPSIS; SPLEEN; SPLENECTOMY; STREPTOCOCCUS PNEUMONIAE;

EID: 84880930673     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318287f1de     Document Type: Article

References (43)

1. Styrt B: Infection associated with asplenia: Risks, mechanisms, and prevention. Am J Med 1990; 88(5N):33N-42N
2. Holdsworth RJ, Irving AD, Cuschieri A: Postsplenectomy sepsis and its mortality rate: Actual versus perceived risks. Br J Surg 1991; 78:1031-1038
3. Altamura M, Caradonna L, Amati L, et al: Splenectomy and sepsis: The role of the spleen in the immune-mediated bacterial clearance. Immunopharmacol Immunotoxicol 2001; 23:153-161
4. Zandvoort A, Timens W: The dual function of the splenic marginal zone: Essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne antigens. Clin Exp Immunol 2002; 130:4-11
5. Haas KM, Poe JC, Steeber DA, et al: B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity 2005; 23:7-18
6. Weill JC, Weller S, Reynaud CA: Human marginal zone B cells. Annu Rev Immunol 2009; 27:267-285
7. Weller S, Braun MC, Tan BK, et al: Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood 2004; 104:3647-3654
8. Wardemann H, Boehm T, Dear N, et al: B-1a B cells that link the innate and adaptive immune responses are lacking in the absence of the spleen. J Exp Med 2002; 195:771-780
9. Offenbartl K, Christensen P, Gullstrand P, et al: Treatment of pneumococcal postsplenectomy sepsis in the rat with human gamma-globulin. J Surg Res 1986; 40:198-201
10. Camel JE, Kim KS, Tchejeyan GH, et al: Efficacy of passive immunotherapy in experimental postsplenectomy sepsis due to Haemophilus influenzae type B. J Pediatr Surg 1993; 28:1441-1444
11. Mikolajczyk MG, Concepcion NF, Wang T, et al: Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations. Clin Diagn Lab Immunol 2004; 11:1158-1164
12. Darville T, Milligan LB, Laffoon KK: Intravenous immunoglobulin inhibits staphylococcal toxin-induced human mononuclear phagocyte tumor necrosis factor alpha production. Infect Immun 1997; 65:366-372
13. Yanagisawa C, Hanaki H, Natae T, et al: Neutralization of staphylococcal exotoxins in vitro by human-origin intravenous immunoglobulin. J Infect Chemother 2007; 13:368-372
14. Aukrust P, Müller F, Svenson M, et al: Administration of intravenous immunoglobulin (IVIG) in vivo-down-regulatory effects on the IL-1 system. Clin Exp Immunol 1999; 115:136-143
15. Smith KG, Clatworthy MR: Fcgamma RIIB in autoimmunity and infection: Evolutionary and therapeutic implications. Nat Rev Immunol 2010; 10:328-343
16. Shankar-Hari M, Spencer J, Sewell WA, et al: Bench-to-bedside review: Immunoglobulin therapy for sepsis-Biological plausibility from a critical care perspective. Crit Care 2012; 16:206
17. Vander Top EA, Perry GA, Gentry-Nielsen MJ: A novel flow cytometric assay for measurement of in vivo pulmonary neutrophil phagocytosis. BMC Microbiol 2006; 6:61
18. White KS, Covington D, Churchill P, et al: Patient awareness of health precautions after splenectomy. Am J Infect Control 1991; 19:36-41
19. Davies JM, Lewis MP, Wimperis J, et al: Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: Prepared on behalf of the British Committee for Standards in Haematology by a working party of the Haemato-Oncology task force. Br J Haematol 2011; 155:308-317
20. Chu DZ, Nishioka K, el-Hagin T, et al: Effects of tuftsin on postsplenectomy sepsis. Surgery 1985; 97:701-706
21. Kubo S, Rodriguez T Jr, Roh MS, et al: Stimulation of phagocytic activity of murine Kupffer cells by tuftsin. Hepatology 1994; 19:1044-1049
22. Mufson MA, Hao JB, Stanek RJ, et al: Clinical features of patients with recurrent invasive Streptococcus pneumoniae disease. Am J Med Sci 2012; 343:303-309
23. Pickering JW, Hoopes JD, Groll MC, et al: A 22-plex chemiluminescent microarray for pneumococcal antibodies. Am J Clin Pathol 2007; 128:23-31
24. Elberse KE, Tcherniaeva I, Berbers GA, et al: Optimization and application of a multiplex bead-based assay to quantify serotype-specific IgG against Streptococcus pneumoniae polysaccharides: Response to the booster vaccine after immunization with the pneumococcal 7-valent conjugate vaccine. Clin Vaccine Immunol 2010; 17: 674-682
25. Huang ZY, Hunter S, Kim MK, et al: The effect of phosphatases SHP-1 and SHIP-1 on signaling by the ITIM-and ITAM-containing Fcgamma receptors Fcgamma RIIB and Fcgamma RIIA. J Leukoc Biol 2003; 73:823-829
26. Blank U, Launay P, Benhamou M, et al: Inhibitory ITAMs as novel regulators of immunity. Immunol Rev 2009; 232:59-71
27. Rhoades CJ, Williams MA, Kelsey SM, et al: Monocyte-macrophage system as targets for immunomodulation by intravenous immunoglobulin. Blood Rev 2000; 14:14-30
28. Abe J, Jibiki T, Noma S, et al: Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. J Immunol 2005; 174:5837-5845
29. Bruhns P, Samuelsson A, Pollard JW, et al: Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 2003; 18:573-581
30. Nimmerjahn F, Ravetch JV: Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26:513-533
31. Tha-In T, Bayry J, Metselaar HJ, et al: Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 2008; 29:608-615
32. Kotb M: Bacterial pyrogenic exotoxins as superantigens. Clin Microbiol Rev 1995; 8:411-426
33. Norrby-Teglund A, Kotb M: Host-microbe interactions in the pathogenesis of invasive group A streptococcal infections. J Med Microbiol 2000; 49:849-852
34. Darenberg J, Ihendyane N, Sjölin J, et al: Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: A European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37:333-340
35. Mosser DM, Edwards JP: Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8:958-969
36. Robinson CM, O'Dee D, Hamilton T, et al: Cytokines involved in interferon-gamma production by human macrophages. J Innate Immun 2010; 2:56-65
37. Park-Min KH, Serbina NV, Yang W, et al: FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 2007; 26:67-78
38. Kazatchkine MD, Kaveri SV: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345:747-755
39. Toyoda M, Pao A, Petrosian A, et al: Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells. Am J Transplant 2003; 3:156-166
40. de Grandmont MJ, Racine C, Roy A, et al: Intravenous immunoglobulins induce the in vitro differentiation of human B lymphocytes and the secretion of IgG. Blood 2003; 101:3065-3073
41. Bayry J, Fournier EM, Maddur MS, et al: Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: A mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun 2011; 36:9-15
42. Lee JC, Park JS, Shepherd SE, et al: Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect Immun 1997; 65:4146-4151
43. Rupp ME, Holley HP Jr, Lutz J, et al: Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007; 51:4249-4254